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Abstract
Background: To evaluate the cytotoxic effect of carbon ion radiotherapy and chemotherapy in glioblastoma cells
in vitro.
Methods and Materials: The human glioblastoma (GBM) cell line U87 was irradiated with photon radiotherapy
(RT) doses of 2 Gy, 4 Gy and 6 Gy. Likewise, irradiation with carbon ions was performed with single carbon doses
of 0.125, 0.5, 2 and 3 Gy. Four chemotherapeutic substances, camptothecin, gemcitabine, paclitaxel and
cisplatinum, were used for single and combination experiments. The assessment of the effect of single and double
treatment on cell viability was performed using the clonogenic growth assay representing the radiobiological gold
standard.
Results: The RBE of carbon ions ranges between 3.3 and 3.9 depending on survival level and dose. All
chemotherapeutic substances showed a clear does-response relationhips. in their characteristic concentrations. For
subsequent combination experiments, two dose levels leading to low and medium reduction of cell survival were
chosen. Combination experiments showed additive effects independently of the drugs’ mechanisms of action.
Paclitaxel and campthothecin demonstrated the most prominent cytotoxic effect in combination with carbon ion
radiotherapy.
Conclusion: In conclusion, combination of carbon ion radiotherapy with chemotherapies of different mechanisms
of action demonstrates additive effects. The most dominant effect was produced by paclitaxel, followed by
camptothecin, as espected from previously published work. The present data serve as an important radiobiological
basis for further combination experiments, as well as clinical studies on combination treatments.
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Background
Novel radiotherapeutic treatment approaches for
patients with glioblastoma (GBM) may enable the radia-
tion oncologist to increase local control, and thus
impact on progression-free survival and overall survival
times; this includes the application of novel radiation
qualities, technical advances, dose and fractionation con-
cepts, as well as combined treatment modalities. In spite
of extensive research, current outcome after the
standard treatment, consisting of postoperative photon
radiotherapy in combination with the alkylating sub-
stance temozolomide (TMZ) is around 15 months [1].
Particle radiotherapy, such as proton or carbon ion
radiation, offers distinct physical characteristics leading
to a more conformal dose distribution: Due to the
inverted dose profile with low dose deposition in the
entry channel of the beam, and high local doses in the
so called Bragg Peak, normal tissue surrounding the
tumor area can be spared, and the integral dose to the
patient can be reduced. Additionally, carbon ions, offer
a higher relative biological effeciveness (RBE) due to the
severe radiation damage produced within the beam
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track [2-4]. Most likely the extent of cell death depends
on difficult-to-repair double-strand breaks of the DNA
[5,6].
Several in vitro studies including our own work have
shown that, for GBM, the RBE of carbon ions is
between 3 and 5, depending on the cell line and the
endpoint [7-9]. Comparable to radiochemotherapy with
protons, we could show that combination of carbon
ions and TMZ lead to an additive effect with respect to
cytotoxicity [7].
Several studies have evaluated the combination of che-
motherapy with radiation using X-rays, however, only
few data is available on the effect of chemotherapy and
carbon ion radiotherapy. It has been hypothesized that,
due to the different radiobiological effects of high-LET
particle beams with special respect to impact on cell
cycle control, combination effects known from photon
radiotherapy in combination with chemotherapeutic
substances of different working mechanisms might be
different for carbon ions. A study by Kitabayashi and
colleagues evaluated carbon ion radiotherapy and differ-
ent chemotherapies in esophagenal cell lines, showing
that combination with docetaxel was the strongest of 4
combinations revealing promising combination effects
[10]. However, for each cancer type distinct groups of
chemotherapy have been shown to be effective, therefore
it may not hold true to transfer such results to cancer
cells in general. Since particle therapy seems a promis-
ing treatment alternative for high-grade primary brain
tumors, the focus of the present analysis was the evalua-
tion of radiochemotherapy with carbon ions in combina-
tion with several chemotherapeutic drugs in glioma
cells.
Materials and methods
Reagents and Cell Culture
The human glioblastoma (GBM) cell line U87 was
obtained from the American Type Culture Collection
(ATCC, Manassas, VA, USA). The cells were cultured in
DMEM supplemented with 10% fetal calf serum (FCS);
they were maintained in culture at 37°C with 5% CO2
and 95% humidity.
Radiotherapy (RT) with photons
Cells were irradiated at room temperature. RT was per-
formed as single exposure to doses of photon RT of 2
Gy, 4 Gy and 6 Gy delivered by a linear accelerator (Fa.
Siemens, Erlangen, Germany).
Radiotherapy (RT) with carbon ions
Irradiation with carbon ion was performed at the Hei-
delberg ion Therapy Center (HIT) with the horizontal
beamline using the rasterscanning technique. To treat
cell cultures with clinically relevant parameters we
delivered the dose as an extended Bragg peak with 103
keV/μm (dose averaged LET). The position of the
Breagg peak was adjusted using a 1 cm acrylic shield,
and cell monolyers were placed in the middle ot the
extended Bragg peak. Single carbon doses of 0.125, 0.5,
2 and 3 Gy were applied.
Chemotherapeutic Treatment
U87 cells were treated with chemotherapy at various
concentrations 4 hours prior to radiation treatment fol-
lowed by a medium change to discontinue drug exposi-
tion. Four chemotherapeutic substances, camptothecin,
gemcitabine, paclitaxel and cisplatinum, were used for
single and combination experiments using differenct
substance-specific concentrations.
For all substances, dose-response-relationships were
generated for single-agent treatment. For combination
experiments, low, i.e. ~70-80% survival, and medium, i.e.
~ 50-60% cell survival, toxicity concentrations were cho-
sen: For paclitaxel, 5 nM and 20 nM, 10 nM and 30 nM
for gemcitabine, 0.5 μM and 1 μM for cisplatinum, and
10 nM and 30 nM for camptothecin.
For combination experiments, glioma cells were irra-
diated immediately after drug wash-out by medium
change.
Clonogenic Assay
The assessment of the effect of single and double treat-
ment on cell viability was performed using the clono-
genic growth assay representing the radiobiological gold
standard. Clonogenic survival is an important criterion
of cell survival in repsonse to antitumor agents because
the final cell death may occur only after additional cell
divisions. For these analyses, the GBM cell lines were
grown under standard conditions. To investigate the
effect of photon and carbon ion irradiation alone, che-
motherapy alone, or the combination of both, on clono-
genic survival, increasing numbers of cells (102 to 5 ×
104) were plated in 25 cm2 flasks (Becton Dickinson,
Heidelberg, Germany) as described previously [11-13].
Cells were kept in the incubator for an attachment per-
iod, and were exposed to compounds and cultures in
various concentrations and returned to the incubator for
10-14 days after which they were stained with crystal
violet (Sigma-Aldrich, Munich, Germany). Colonies
were counted by microscopic inspection and plating effi-
ciency as well as clonogenic survival were calculated.
Only colonies with a minimum of 50 cells were counted.
Plating efficiencies ranged from 4% to 12% for separate
culture preparations. Each experiment was repeated on
three separate days, and on each day triplicates of each
dose and treatment combination was performed. Mean
values (and standard deviations) were only calculated
from independent experiments (separate days).
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Results
Clonogenic survival and determination of RBE
We calculated clonogenic survival after increasing doses
of photon and carbon ion radiotherapy on U87 cells;
carbon ion radiotherapy demonstrated a steeper dose-
response-relationship revealing a stronger cytotoxic
effect in glioblastoma cells compared to photon radio-
therapy (Figure 1). From these values, we calculated the
RBE from linear-quadratic-fits (LQ-fits) as a function of
survival level (Figure 2A) or carbon ion dose (Figure
2B). The RBE ranges between 3.3 and 3.9 depending on
survival level and dose.
Clonogenic survival after single-agent chemothrapies
The in vitro survival curves of U87 treated with increas-
ing concentrations of gemcitabine, paclitaxel, camp-
tothecin and cisplatinum are shown in Figure 3. All
substances showed a clear does-response relationship in
their characteristic concentrations. For subsequent com-
bination experiments, two dose levels leading to low and
medium reduction of cell survival were chosen.
Evaluation of cytotoxic effect of radiation and
chemotherapy
Combination experiments of 4 chemotherapeutic drugs
cisplatinum, gemcitabine, paclitaxel and camptothecin
(Figure 4 A-D). For generation of the survival curves
within each independent experiment, PE-values mea-
sured in triplicate for each treatment condition and the
averaged values were normalized to the respective num-
ber for the untreated sample. Respective PE-values
obtained in the combination experiments were normal-
ized to a drug control yielding surviving fractions
diplayed in the graphical representation. Results showed
additive effects independently of the drugs’ mechanisms
of action. No agent demonstrated a significantly higher
combination effect compared to the other substances.
Bar diagrams of surviving fractions of U87 cells mea-
sured in vitro as well as calculated from independent
toxicities obtained from single agent experiments (Fig-
ure 5). For all substances additive effects could be
observed. This holds true also for the more effective
agents, paclitacel and camptothecin, resulting in a pro-
minent cytotoxic effect for the combination with carbon
ions.
Figure 1 Clonogenic survival after photon and carbon ion
radiotherapy. Carbon ion radiotherapy reveals a stronger cytotoxic
effect in glioblastoma cells compared to photon radiotherapy.
Figure 2 Relative biological effectiveness (calculated from LQ-
fits) as a function of survival level (A) or carbon ion dose (B).
The RBE ranges between 3.3 and 3.9 depending on survival level
and dose.
Figure 3 Clonogenic survival of U87 cells treated with
increasing doses of cisplatinum (A), camptothecin (B),
gemcitabine (C) and paclitaxel (D).
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Discussion
The present study evaluated the combination of differ-
ent chemotherapeutic substances in combination with
photon and carbon ion radiotherapy with respect to cell
survival in glioblastoma cells. The work shows additive
effects for all drugs independently of their mechanisms
of action, however, revealing the strongest interactive
effect for paclitaxel and campthothecin.
Until now, few data is available on the combination of
chemotherapy and high-LET particle beams, such as
carbon ion radiotherapy. From a clinical perspective car-
bon ion radiotherapy might be a promising treatment
alternative in patients with GBM, which has been
reported by a Japanese study [14]. The potential additive
value of a carbon ion boost is currently evaluated in a
randomized clinical trial [15]. This clinical work had
been based on a previous experimental study from our
group: We could show that combination of temozolo-
mide, an alkylating chemotherapeutic drug, and carbon
ion radiotherapy leads to an additive effect, comparable
to photons [7].
To further exploit a possible combination of other
drugs with alternative mechanisms, we included agents
commonly not in clinical use from GBM into the pre-
sent work to identify the combination effect with high-
LET carbon ion radiotherapy. Four different chemother-
apeutics were used, and paclitaxel as well as camptothe-
cin showed the strongest additive effects in combination
with carbon ions, compared to gemcitabine and cisplati-
num. These results are in line with a previous study
published by Kitabayashi et al., evaluating different che-
motherapeutic substances in esophageal squamous cell
carcinoma lines [10]. The authors could show that doce-
taxel and heavy ion radiotherapy lead to the most pro-
minent reduction of cell survival in vitro and in vivo.
Novel treatment approaches such as molecularly-tar-
geted subtances, might potentiate the effect of carbon
ion radiotherapy, and preclinical work is currently
ongoing. Only recently, Kano and collegues evaluated
histone-deacetylase inhibitors in combination with car-
bon ions in esophageal cell lines [16]; a radiosensitizing
effect could be observed, and tumor growth was signifi-
cantly suppressed by the combination of carbon ion
radiotherapy with the histone deacetylase inhibitor in
comparison to either agent alone. Similar data have
been reported for sarcoma cell lines using a combina-
tion of a pan-HDAC inhibitor (HDACI) suberoylanilide
hydroxamic acid (SAHA) in combination with carbon
ion radiotherapy [17]. The medication lead to an
increase of sensitivity to carbon ion radiotherapy along
with an increase of double strang breaks and apoptosis.
In the clinical setting, particle therapy has to be
included into existing treatment protocols, which in
most cases include radiation and chemotherapy. There-
fore, when introducing a new radiation quality, the
effect of combined treatment is essential information to
calculated risks of side effects, and therapeutic ratios.
This manuscript presents the first extensive evaluation
of the combination effect of carbon ions and che-
motherapeutic substances of different mechanisms of
action, focussing on GBM cell lines. Therefore the pre-
sent work represents essential radiobiological informa-
tion for subsequent pre-clinical as well as clinical
applications, leading to the conclusion that when such
substances are combined with carbon ions no specific
reductions in dosing with respect to cytotoxicity in the
Figure 4 Combination experiments of 4 chemotherapeutic
drugs (cisplatinum (A), gemcitabine (B), paclitaxel (C) and
camptothecin (D). Results showed additive effects independently
of the drugs’ mechanisms of action.
Figure 5 Bar diagrams of surviving fractions of U87 cells (X X-
rays, C Carbon ions, • expected survival according to
independent toxicity). For all substances additive effects could be
observed. In U87, paclitaxel and campthothecin demonstrated the
most prominent cytotoxic effect in combination with carbon ion
radiotherapy.
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radiation area must be undertaken compared to com-
bined treatments with photons. The results also pertain
the aspect of biological plan optimization in carbon ion
radiotherapy: Biologic plan optimization is used for all
treatment plans in clinical practice; in Heidelberg, the
local effect model (LEM) integrating various parameters
has been established in clinical routine [3,18,19]. Several
clinical and theoretical studies have focussed on radio-
biological parameters in GBM, and Jones and colleagues
estimated ab ratio, doubling time and other parameters,
as well as equivalent biologial radiation dose to temozo-
lomide chemotherapy [20]. These data may serve as an
essential basis for further combination treatments, and
the present preclinical results underline that it should
hold true that biological treatment planning can be
transferred also into the setting of radiochemotherapy
without having to adjust the known input parameters
for each tumor cell type. In our own previous work, we
have confirmed this hypothesis [7].
Conclusion
In conclusion, combination of carbon ion radiotherapy
with chemotherapies of different mechanisms of action
demonstrates additive effects. The most dominant effect
was produced by paclitaxel, followed by camptothecin,
as espected from previously published work. The pre-
sent data serve as an important radiobiological basis for
further combination experiments, as well as clinical stu-
dies on combination treatments.
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